Mycobacterium welchii Vaccine Granuloma – A Cautionary Tale
Authors:
Open Access
- 1 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 13 (2) , 178-182
Abstract
Background: Mycobacterium welchii (Mycobacterium w) vaccine was one of the many strategies used to both treat and prevent coronavirus disease 2019 (COVID-19) infection. We report the results of a retrospective analysis of 15 cases with vaccine-site granulomas after administration of prophylactic Mycobacterium w vaccine as part of a trial for COVID-19 and our experience in managing those cases. Methods: This was a retrospective analysis of 15 patients with vaccine-site granulomas who were given the vaccine as a prophylactic measure as part of a trial with informed consent. Results: The mean average age of cases was 37 and the male-to-female ratio was 1:0.87. All of the patients developed erythematous tender nodules over the injection sites within a month of receiving the inoculations. Mycobacterial cultures and cartridge-based nucleic acid amplification tests yielded negative results. Skin biopsy revealed granulomatous dermatitis with acid-fast bacilli positivity. A diagnosis of noninfective granulomatous dermatitis was made. Treatment started with analgesics and anti-inflammatory agents. Systemic antibiotics were required in 9/15 patients. Patients are being followed up with no reported recurrence till date. Conclusion: The possibility of injection-site granuloma should be taken into the risk–benefit analysis for the administration of Mycobacterium w vaccine and the patients should be counseled as such. Patients with persistent ulceration respond to combinations of doxycycline, ofloxacin, and clarithromycin.Keywords
This publication has 14 references indexed in Scilit:
- Non-infective granulomatous dermatitis following Mycobacterium w injectionsIndian Journal of Dermatology, Venereology and Leprology, 2022
- Injection site reactions associated with the use of Mycobacterium w in COVID‐19 patientsInternational Journal of Dermatology, 2022
- Nontuberculous MycobacteriumInternational Journal of Mycobacteriology, 2021
- Mycobacterium W. - An unusual side effectIndian Journal of Tuberculosis, 2021
- A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral wartsIndian Journal of Dermatology, Venereology and Leprology, 2019
- BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained ImmunityCell Host & Microbe, 2018
- Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trialScientific Reports, 2017
- Cutaneous Granulomas Associated With Interferon TherapyThe American Journal of Dermatopathology, 2016
- Generalized granulomatous dermatitis followingMycobacterium w (Mw)immunotherapy in lepromatous leprosyDermatologic Therapy, 2016
- Intralesional Injection ofMycobacterium wVaccine vs Imiquimod, 5%, Cream in Patients With Anogenital WartsJAMA Dermatology, 2014